Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. According to AstraZeneca, this collaboration agreement is also expected to accelerate Korean bio-health innovation. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Plant 3 as well as drug product to support AstraZeneca’s biologics therapeutics, which…